These solutions, the Lung Density Analysis II (LDA-II) workflow for Intuition and the Emergency Lung AI Suite, provide two deployment options for rapid access to lung segmentation and quantification tools that can be applied to a wide range of lung illnesses and have been optimized to adapt to the latest disease presentation states

May 7, 2020 — As COVID-19 makes its way across the globe, our customers are urgently connecting with us to share cases, ideas, and needs. TeraRecon responded by diverting the majority of our engineering and clinical resources to develop and release two innovative and practical solutions in just over three weeks. TeraRecon designed the solutions to address the urgent crisis as well as a much broader view of our customers’ needs—to deliver lasting value as an integrated part of any customers’ lung program or enterprise artificial intelligence (AI) roll-out. We are committed helping our customers leverage technology to extend the reach and responsiveness of care.

These solutions, the Lung Density Analysis II (LDA-II) workflow for Intuition and the Emergency Lung AI Suite, provide two deployment options for rapid access to lung segmentation and quantification tools that can be applied to a wide range of lung illnesses and have been optimized to adapt to the latest disease presentation states. 

Lung Density Analysis II (LDA-II) for Intuition

The newly released LDA-II allows TeraRecon Intuition customers to upgrade their advanced visualization systems with a custom lung workflow. By leveraging Intuition's capabilities in lung segmentation, volumetric histogram analysis, and automation, physicians quickly receive colorized densities and lung composition values that can be analyzed and quantified with little to no manual editing required.  LDA-II is available as a remotely installed upgrade to Intuition customers or comes included as standard functionality with a subscription to TeraRecon’s new AI-ready Intuition Titanium Suite.

Emergency Lung AI Suite

The newly released Emergency Lung AI Suite provides fast access to lung density analysis tools across the enterprise and securely extends access to physicians working remotely. This cloud-based rapid response platform allows physicians to upload cases, anonymize patient data, process the LDA-II algorithm, and receive notification of results regardless of where they are located. Whether in the emergency department, radiology, pulmonology, or at home, this pure cloud offering requires no installation and may be integrated to diagnostic and point-of-care solutions in minutes. The Emergency Lung AI Suite is extensible to other clinical use cases within a health system’s imaging and crisis readiness infrastructure.

For more information: www.terarecon.com


Related Content

News | Computed Tomography (CT)

May 12, 2026 – Bracco Imaging S.p.A. has purchased a mobile photon-counting CT scanner from MARS Bioimaging to support ...

Time May 20, 2026
arrow
Feature | Enterprise Imaging | Kyle Hardner

For radiology departments, the imbalance between surging imaging volume and a shortage of trained radiologists is taking ...

Time May 20, 2026
arrow
News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27, 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
Feature | Information Technology

AT A GLANCE Organization: Expert Radiology Management Services, LLC Specialty: Subspecialty teleradiology — neuro and ...

Time May 01, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True ...

Time April 03, 2026
arrow
Subscribe Now